Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Study of outcomes following ibrutinib to zanubrutinib transition in Waldenström patients on ASPEN finds ibrutinib treatment-emergent AEs of interest did not recur/worsen, disease response maintained or improved in 96% (44/46).”
Title: Outcomes following transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from ASPEN
Authors: Ramon Garcia-Sanz, Roger G. Owen, Wojciech Jurczak, Meletios Athanasios Dimopoulos, Helen McCarthy, Gavin Cull, Stephen S. Opat, Jorge J. Castillo, Marie José Kersten, Björn E. Wahlin, Sebastian Grosicki, Radha Prathikanti, Tian Tian, Heather Allewelt, Aileen Cohen, Constantine S. Tam
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski on OncoDaily.
